- Also known as
- Reta · LY3437943 · GGG tri-agonist
- Class
- GIP, GLP-1 and glucagon receptor agonist
- Form
- Lyophilised powder in 10 mg, 20 mg and 30 mg vials and a pre-filled pen
- Sizes
- 10 mg · 20 mg · 30 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL · 20 mg: 3 mL · 30 mg: 3 mL
What is Retatrutide?
Retatrutide is a GIP, GLP-1 and glucagon receptor agonist, and that classification is where the published work starts. Published work on it is in human. The name covers the same material written several ways in the literature, including Reta, LY3437943 and GGG tri-agonist. Its sequence is recorded as Single peptide chain with activity at three receptors; developed as LY3437943.. 6 of the 6 studies listed below are controlled trials in people. Borealis Peptides supplies it as lyophilised powder in 10 mg, 20 mg and 30 mg vials and a pre-filled pen for in-vitro laboratory research. It is not a medicine and is not for use in humans or animals.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Jastreboff AM et al.2023 · N Engl J Med · PMID 37366315 | Human, phase 2 randomised controlled trial in adults with obesity (n=338) | 1, 4, 8 or 12 mg once weekly, subcutaneous (4 and 8 mg arms started at 2 or 4 mg; 12 mg started at 2 mg), vs placebo | 48 weeks | Mean body weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg) vs −2.1% with placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. |
| Bajaj HS et al.2026 · Lancet · PMID 42250575 | Human, phase 3 randomised controlled trial in adults with type 2 diabetes (n=537) | 4, 9 or 12 mg once weekly, subcutaneous, vs placebo | 40 weeks | HbA1c fell by 1.69%, 1.86% and 1.94% with 4, 9 and 12 mg vs 0.81% with placebo, and body weight changed by −11.5%, −13.9% and −15.3% vs −2.6%. Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo. |
| Urva S et al.2022 · Lancet · PMID 36354040 | Human, phase 1b randomised multiple-ascending dose trial in type 2 diabetes (n=72) | 0.5, 1.5, 3, 3/6 or 3/6/9/12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg | 12 weeks | Treatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. The primary outcome was safety and tolerability. |
| Sanyal AJ et al.2024 · Nat Med · PMID 38858523 | Human, phase 2a randomised controlled substudy in adults with MASLD and ≥10% liver fat (n=98) | 1, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo | 48 weeks (liver fat primary endpoint at 24 weeks) | Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg) and −82.4% (12 mg) vs +0.3% with placebo. Normal liver fat (<5%) was reached by 27% to 86% of the retatrutide groups and 0% on placebo. |
| Coskun T et al.2025 · Lancet Diabetes Endocrinol · PMID 40609566 | Human, phase 2 randomised controlled body-composition substudy in type 2 diabetes (n=189 enrolled; 103 with both DXA scans) | 0.5, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg | 36 weeks | Total fat mass measured by DXA fell by 4.9% (0.5 mg), 15.2% (4 mg), 26.1% (8 mg) and 23.2% (12 mg), compared with 2.6% on dulaglutide and 4.5% on placebo. |
| Kanu C et al.2025 · Diabetes Obes Metab · PMID 40916752 | Human, exploratory analysis of a phase 2 randomised controlled trial in type 2 diabetes (n=275) | 0.5, 4, 8 or 12 mg once weekly, vs placebo or dulaglutide 1.5 mg | 24 and 36 weeks | Participants on 4 mg or more reported greater reductions in overall appetite, hunger and prospective food consumption than placebo at week 24. Lower perceived hunger and disinhibition correlated with weight reduction at week 36. |
What these studies don't show: Trials exist; their scope is narrower than it first appears. Trial populations are selected, endpoints are often surrogate measures rather than outcomes, and follow-up rarely runs long. None of it establishes safety outside the conditions each trial ran under. Knowing the vial holds what the label says is not the same as knowing the compound does anything.
Every study links to its PubMed record. See all Retatrutide studies in the research library →
Retatrutide price in Canada: 10mg, 20mg and 30mg vials
Buy Retatrutide in Canada in 3 vial sizes, plus pre-filled pens and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $87.00 | $8.70/mg |
| 20 mg | $138.00 | $6.90/mg |
| 30 mg | $198.00 | $6.60/mg |
Pens, kits and other formats
Is Retatrutide available in Canada?
Retatrutide does not appear in the Drug Product Database as an authorized product. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. Read more →
Side effects reported in studies
Where a cited study reported on tolerability, its wording is carried over unchanged below. Human work of this size does not establish a safety profile. Read more →
Retatrutide FAQ
What is Retatrutide?
The literature describes Retatrutide as GIP, GLP-1 and glucagon receptor agonist. The published work on it is in human. Borealis Peptides supplies it as lyophilised powder in 10 mg, 20 mg and 30 mg vials and a pre-filled pen for in-vitro laboratory research. Nothing here is a medicine; it is not for human or veterinary use. The table on this page gives each study, its model and its reported result.
Where can I buy Retatrutide in Canada?
It ships within Canada from stock we hold, in 10 mg, 20 mg and 30 mg vials. Nothing leaves without HPLC confirmation of identity and purity for that batch. Borealis Peptides accepts research orders only, and ships to research and business addresses.
Is Retatrutide legal in Canada?
Retatrutide does not appear in the Drug Product Database as an authorized product. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. Borealis Peptides supplies it for in-vitro laboratory research only, not for human or veterinary use. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much Retatrutide should I use?
Borealis Peptides gives no dosing, protocols or reconstitution volumes, and will not provide them on request. In laboratory work the amount follows from the study design, which a supplier cannot sensibly set. The figures on this page are what specific published studies used in their own models: a record of what was done, not a recommendation.
What human evidence is there for Retatrutide?
Of the 6 studies cited, 6 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
Does Retatrutide need refrigeration?
Sealed vials are held at −20 °C, dry and out of the light. After mixing, storage is 2–8 °C. Ambient transit does not harm the dry powder, which should be refrigerated once received. What degrades a lyophilised peptide is light and temperature cycling rather than transit time.
Does Retatrutide need bacteriostatic water?
The pre-filled pen comes already in solution. Only the lyophilised vial is supplied dry, and that is the one format bacteriostatic water applies to. It is sold separately. HPLC runs on each batch, and the certificate you receive refers to the batch you were sent.
How is the purity of Retatrutide confirmed?
Identity and purity are confirmed by HPLC for each batch, not once per product. The certificate names the batch it belongs to, and that batch number is on the vial, so a result can be traced back to the exact material that produced it. Ask with your order number and we send it.
How does Retatrutide compare with Tirzepatide and Cagrilintide?
Each has its own published record, and comparing them is a matter of reading both. Tirzepatide and Cagrilintide have 8 cited studies and 8 cited studies on their page against 6 here. Reading both tables, with the models each used, is the comparison worth making.
Why is Retatrutide named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory concerns material sold for people to inject without authorization. Borealis Peptides supplies research material for laboratory use and sells nothing for injection or for any use in a person, which is the line that advisory draws.
Compare with
Related compounds
Cagrilintide
Long-acting amylin analogue (amylin receptor agonist)
Add 2 more to save 4%
AOD-9604
Modified C-terminal fragment of human growth hormone
Add 2 more to save 4%
SLU-PP-332
Synthetic pan-ERR (ERRα/β/γ) agonist, small molecule
Add 2 more to save 4%